Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE combined with camrelizumab and targeted therapy for unresectable advanced hepatocellular carcinoma
ChiCTR2000039508Phase 4Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in hepatocellular carcinoma (HCC), sponsored by Shandong Cancer Hospital. Primary endpoints: progression-free survival and objective response rate. Started Nov 2020; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000039508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039508.